CAMBRIDGE,‌ Mass. – August 28, ‍2025 – Nuvalent, Inc. (Nasdaq: Novl) announced today that ‌its‍ management team⁢ will present at the Morgan⁣ Stanley Global⁢ Healthcare Conference on September 9, 2025, ⁤at 11:00 AM ET. The⁢ presentation will be webcast live and archived for 30 days following the event. the webcast can ⁢be accessed at Nuvalent’s website.
⁣ ⁢

About Nuvalent

‍ ‍Nuvalent, Inc.is a clinical-stage biopharmaceutical company dedicated to developing precisely ⁢ targeted‍ therapies for cancer patients. The company aims to address ‍limitations of existing⁤ kinase inhibitor therapies,​ focusing on ‍overcoming resistance, reducing adverse ‍effects, improving brain penetration, and achieving more durable responses.Nuvalent’s approach leverages deep expertise in chemistry and structure-based drug design.
​

Currently,Nuvalent is advancing a pipeline of ⁣investigational candidates targeting ROS1-positive,ALK-positive,and ⁤HER2-altered ⁢non-small ​cell lung cancer. The company also has multiple revelation-stage ‌research programs underway. As‌ of August​ 28,2025,Nuvalent is traded on the Nasdaq stock exchange under the ticker symbol ⁤ Novl.

Understanding Kinase Inhibitors and Targeted Therapies

‍ ⁤ ​Kinases are enzymes​ that​ play a crucial role in cell signaling, and their dysregulation is frequently enough ⁣implicated in ⁣cancer development. Kinase inhibitors are drugs designed to block ⁣the activity of‍ these enzymes, thereby disrupting cancer cell⁤ growth ‍and​ survival. however, cancer cells can develop resistance to these inhibitors through​ various mechanisms, including ‌mutations in the⁢ kinase ⁢itself or activation ​of⁤ choice signaling pathways.

‌ ⁢ Targeted therapies, like those being developed by⁣ Nuvalent, aim ⁢to overcome these resistance mechanisms by designing drugs that⁤ are more selective for the target kinase or that can circumvent⁢ the resistance pathways. ‌ Structure-based drug design utilizes the three-dimensional structure of the target⁢ protein to rationally design molecules that bind⁤ with‍ high affinity and specificity.
⁣